D. Western Therapeutics Institute (TYO:4576) has entered into a joint research agreement with Professor Hitoshi Kasai of Tohoku University to develop new formulations for treating eye diseases, according to a Monday filing on the Tokyo Stock Exchange.
The collaboration, which will be conducted through the Aoba Foundation For The Promotion of Engineering, focuses on addressing the unmet medical needs in retinal diseases like retinitis pigmentosa, diabetic retinopathy, and age-related macular degeneration, as well as conditions like cataracts that currently rely on surgery.
The joint research will explore the development of organic nanomaterials and nanodrugs to enhance drug efficacy and intraocular penetration.
The company said it aims to expand its pipeline and meet the growing demand for drug-based treatments.
Price (JPY): $108.00, Change: $+2.0, Percent Change: +1.89%
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。